Aronow Wilbert S
Cardiology Division, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA.
Cardiol Rev. 2009 May-Jun;17(3):136-46. doi: 10.1097/CRD.0b013e3181a270f8.
Underlying causes of ventricular tachycardia (VT) or complex ventricular arrhythmias (VA) should be treated if possible. Antiarrhythmic drugs should not be administered to treat asymptomatic individuals with complex VA and no heart disease. Beta-blockers are the only antiarrhythmic drugs that have been documented to reduce mortality in patients with VT or complex VA. Radiofrequency catheter ablation of VT has been beneficial in treating selected patients with arrhythmogenic foci of monomorphic VT. The automatic implantable cardioverter-defibrillator (AICD) is the most effective treatment for patients with life-threatening VT or ventricular fibrillation. Patients with AICDs should be treated with biventricular pacing, not with dual-chamber rate-responsive pacing at a rate of 70/min. Patients with AICDs should also be treated with beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin blockers.
室性心动过速(VT)或复杂性室性心律失常(VA)的潜在病因若有可能应予以治疗。对于无心脏病的复杂性VA无症状个体,不应给予抗心律失常药物治疗。β受体阻滞剂是唯一已被证明可降低VT或复杂性VA患者死亡率的抗心律失常药物。VT的射频导管消融术对治疗某些有单形性VT致心律失常病灶的患者有益。自动植入式心律转复除颤器(AICD)是治疗有危及生命的VT或心室颤动患者的最有效方法。植入AICD的患者应接受双心室起搏治疗,而不是以70次/分钟的频率进行双腔频率应答起搏。植入AICD的患者还应接受β受体阻滞剂、他汀类药物和血管紧张素转换酶抑制剂或血管紧张素阻滞剂治疗。